Approval Year
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
623817
Created by
admin on Sat Dec 16 11:53:31 UTC 2023 , Edited by admin on Sat Dec 16 11:53:31 UTC 2023
|
||
|
FDA ORPHAN DRUG |
455114
Created by
admin on Sat Dec 16 11:53:31 UTC 2023 , Edited by admin on Sat Dec 16 11:53:31 UTC 2023
|
||
|
EU-Orphan Drug |
EU/3/18/2096
Created by
admin on Sat Dec 16 11:53:31 UTC 2023 , Edited by admin on Sat Dec 16 11:53:31 UTC 2023
|
||
|
FDA ORPHAN DRUG |
643118
Created by
admin on Sat Dec 16 11:53:31 UTC 2023 , Edited by admin on Sat Dec 16 11:53:31 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
UVJ7NL8S2P
Created by
admin on Sat Dec 16 11:53:31 UTC 2023 , Edited by admin on Sat Dec 16 11:53:31 UTC 2023
|
PRIMARY | |||
|
1947415-68-0
Created by
admin on Sat Dec 16 11:53:31 UTC 2023 , Edited by admin on Sat Dec 16 11:53:31 UTC 2023
|
PRIMARY | |||
|
DB15258
Created by
admin on Sat Dec 16 11:53:31 UTC 2023 , Edited by admin on Sat Dec 16 11:53:31 UTC 2023
|
PRIMARY | |||
|
C170061
Created by
admin on Sat Dec 16 11:53:31 UTC 2023 , Edited by admin on Sat Dec 16 11:53:31 UTC 2023
|
PRIMARY | |||
|
10617
Created by
admin on Sat Dec 16 11:53:31 UTC 2023 , Edited by admin on Sat Dec 16 11:53:31 UTC 2023
|
PRIMARY | |||
|
m12239
Created by
admin on Sat Dec 16 11:53:31 UTC 2023 , Edited by admin on Sat Dec 16 11:53:31 UTC 2023
|
PRIMARY | |||
|
GH-02
Created by
admin on Sat Dec 16 11:53:31 UTC 2023 , Edited by admin on Sat Dec 16 11:53:31 UTC 2023
|
PRIMARY | |||
|
Imlifidase
Created by
admin on Sat Dec 16 11:53:31 UTC 2023 , Edited by admin on Sat Dec 16 11:53:31 UTC 2023
|
PRIMARY |
ACTIVE MOIETY